ID   HT-1376
AC   CVCL_1292
SY   HT1376; HT 1376; HT 1376.T
DR   BTO; BTO:0003461
DR   CLO; CLO_0004268
DR   CLO; CLO_0004279
DR   EFO; EFO_0002203
DR   CLDB; cl1743
DR   CLDB; cl1744
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1472
DR   ATCC; CRL-7927
DR   BCRC; 60058
DR   BioGRID_ORCS_Cell_line; 414
DR   BioSample; SAMN01821564
DR   BioSample; SAMN01821635
DR   BioSample; SAMN03472820
DR   BioSample; SAMN10988225
DR   cancercelllines; CVCL_1292
DR   Cell_Model_Passport; SIDM00678
DR   ChEMBL-Cells; CHEMBL3308398
DR   ChEMBL-Cells; CHEMBL3308610
DR   ChEMBL-Targets; CHEMBL612258
DR   ChEMBL-Targets; CHEMBL614664
DR   CLS; 305100
DR   Cosmic; 715761
DR   Cosmic; 760481
DR   Cosmic; 845562
DR   Cosmic; 907066
DR   Cosmic; 925821
DR   Cosmic; 928815
DR   Cosmic; 943733
DR   Cosmic; 1046691
DR   Cosmic; 1285118
DR   Cosmic; 1285987
DR   Cosmic; 1927303
DR   Cosmic; 2050444
DR   Cosmic; 2057449
DR   Cosmic; 2444252
DR   Cosmic; 2686096
DR   Cosmic-CLP; 907066
DR   DepMap; ACH-000724
DR   DSMZ; ACC-397
DR   DSMZCellDive; ACC-397
DR   ECACC; 87032402
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS266UUE
DR   ENCODE; ENCBS956LPK
DR   GDSC; 907066
DR   GEO; GSM136230
DR   GEO; GSM142305
DR   GEO; GSM142310
DR   GEO; GSM827432
DR   GEO; GSM887139
DR   GEO; GSM888210
DR   GEO; GSM1374560
DR   GEO; GSM1574553
DR   GEO; GSM1669911
DR   IARC_TP53; 3720
DR   IGRhCellID; HT1376
DR   IZSLER; BS TCL 70
DR   KCLB; 21472
DR   LiGeA; CCLE_036
DR   LINCS_LDP; LCL-1712
DR   PharmacoDB; HT1376_628_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1292
DR   PubChem_Cell_line; CVCL_1292
DR   Wikidata; Q54896503
RX   PubMed=191628;
RX   PubMed=3518877;
RX   PubMed=3708594;
RX   PubMed=6244232;
RX   PubMed=7787250;
RX   PubMed=8873383;
RX   PubMed=9850064;
RX   PubMed=11416159;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=24459064;
RX   PubMed=25997541;
RX   PubMed=26055179;
RX   PubMed=26589293;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: Caucasian.
CC   Doubling time: 31 hours (PubMed=3708594); 31 hours (PubMed=26055179); ~60 hours (DSMZ=ACC-397).
CC   HLA typing: A*24:02,24:02; B*15:01,15:01; C*03:03,03:03; DQA1*01:02,03:02; DQB1*06:03,06:03; DRB1*13:27,14:121 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (PubMed=27270441).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (PubMed=7787250; PubMed=9850064).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.48%; Native American=1.4%; East Asian, North=1.78%; East Asian, South=1.08%; South Asian=9.04%; European, North=26.62%; European, South=58.6% (PubMed=30894373).
CC   Misspelling: HT-137; ChEMBL-Targets=CHEMBL614664; ChEMBL-Cells=CHEMBL3308610.
CC   Misspelling: HT-1367; PubMed=29732388.
CC   Discontinued: ATCC; CRL-7927; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=11416159; PubMed=27270441
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 11,14
ST   D18S51: 14,15
ST   D19S433: 16
ST   D21S11: 26,32.2 (PubMed=11416159)
ST   D21S11: 26,33.2 (DSMZ)
ST   D2S1338: 17,19
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   D8S1179: 14,16
ST   FGA: 21,22
ST   Penta D: 11
ST   Penta E: 7,13
ST   TH01: 7,9.3 (KCLB; PubMed=11416159)
ST   TH01: 7,10 (ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=27270441)
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   PubMed=191628; DOI=10.1093/jnci/58.4.881;
RA   Rasheed S., Gardner M.B., Rongey R.W., Nelson-Rees W.A., Arnstein P.;
RT   "Human bladder carcinoma: characterization of two new tumor cell lines
RT   and search for tumor viruses.";
RL   J. Natl. Cancer Inst. 58:881-890(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=24459064; DOI=10.1007/s13277-013-1604-3;
RA   Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I.P.,
RA   Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R.,
RA   Oliveira P., Santos L.;
RT   "Genomic characterization of three urinary bladder cancer cell lines:
RT   understanding genomic types of urinary bladder cancer.";
RL   Tumor Biol. 35:4599-4617(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//